News Immatics and Editas Medicine Enter Strategic Research Collaboration and Licensing Agreement to Combine Gamma-Delta T Cell Adoptive Cell Therapies and Gene Editing for the Treatment of Cancer by trophic 07 June, 2022
News Immatics Announces First Quarter 2022 Financial Results and Business Update by trophic 02 June, 2022
News Immatics and Bristol Myers Squibb Expand Strategic Alliance to Develop Gamma Delta Allogeneic Cell Therapy Programs by trophic 02 June, 2022
